Johnson & Johnson's $2 Billion Acquisition of Cancer Drug Developer Ambrx Biopharma
Johnson & Johnson has announced its $2 billion acquisition of Ambrx Biopharma, a company specializing in cancer treatment through antibody-drug conjugates (ADCs). This move reflects J&J's strategy to fill a revenue gap expected in 2025 and follows similar investments by other major pharmaceutical companies. The acquisition is expected to enhance J&J's oncology pipeline and provide opportunities for precision biologics in cancer treatment.
